We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Hematology-Oncology

Amivantamab Falls Short of Tumor Shrinkage in Recurrent or Metastatic Adenoid Cystic Carcinoma, but Disease Stabilization Was Common

MedXY Editorial Team•Apr 20, 2026•Hematology-Oncology
amivantamabEGFR METphase 2 trial

Structured Outline

1. Title

Amivantamab Falls Short of Tumor Shrinkage in Recurrent or Metastatic Adenoid Cystic Carcinoma, but Disease Stabilization Was Common

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: Long-Term Results From the DOREMY Phase 2 TrialLong-term follow-up from the DOREMY phase 2 trial shows that reduced-dose preoperative radiotherapy for localized myxoid liposarcoma achieved excellent local control with relatively low toxicity.Jun 10, 2026Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: Long-Term Results from the Phase 2 DOREMY TrialA long-term phase 2 trial found that reduced-dose preoperative radiotherapy followed by surgery provided excellent local control and acceptable toxicity in localized myxoid liposarcoma.Jun 10, 2026Phase 2 Study of XP-8121: Once-Weekly Subcutaneous Levothyroxine for Adult HypothyroidismA Phase 2 trial found that once-weekly subcutaneous levothyroxine (XP-8121) was generally well tolerated and suggested a dose conversion of about four times the daily oral dose for adults with hypothyroidism.Jun 5, 2026Beyond Objective Responses: Amivantamab Demonstrates Significant Clinical Benefit in Recurrent Adenoid Cystic Carcinoma
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
A Phase 2 clinical trial of amivantamab, an EGFR-MET bispecific antibody, in recurrent or metastatic adenoid cystic carcinoma (ACC) showed a 72.2% clinical benefit rate. While the primary objective response rate was low, the high rate of di
Mar 2, 2026
Amivantamab Plus Lazertinib Shows Promising Activity in Atypical EGFR-Mutant Advanced NSCLC: CHRYSALIS‑2 Cohort C ResultsIn CHRYSALIS‑2 Cohort C, the amivantamab plus lazertinib combination produced a 52% ORR and durable responses (mDoR 14.1 months) in advanced NSCLC with atypical EGFR mutations, with higher activity in treatment‑naïve patients and an expecteDec 8, 2025
CM313, a Novel Anti-CD38 Monoclonal Antibody, Demonstrates Promising Efficacy and Safety in Persistent or Chronic Primary Immune Thrombocytopenia: Insights from a Phase 2 Randomized TrialThe phase 2 trial shows that CM313 significantly improves platelet response rates and duration with manageable safety in adults with persistent or chronic primary immune thrombocytopenia.Oct 31, 2025